Visceral Leishmaniasis: Recent Advances in Diagnostics and Treatment Regimens.
Diagnosis
Treatment
Visceral leishmaniasis
Journal
Infectious disease clinics of North America
ISSN: 1557-9824
Titre abrégé: Infect Dis Clin North Am
Pays: United States
ID NLM: 8804508
Informations de publication
Date de publication:
03 2019
03 2019
Historique:
entrez:
5
2
2019
pubmed:
5
2
2019
medline:
8
11
2019
Statut:
ppublish
Résumé
Diagnostic advances in visceral leishmaniasis include the development of the rK39 and rK28 rapid diagnostic test. The direct agglutination test is also increasingly used, as well as conventional and real-time polymerase chain reaction, which also performs well on peripheral blood. The choice of treatment for visceral leishmaniasis depends on the geographic region where the infection is acquired. Liposomal amphotericin B is generally found to be safe and effective in most endemic regions of the world; antimonials still remain to be the most effective in eastern Africa despite its high toxicity. Combination therapy is increasingly explored. Immunosuppressed patients require adapted diagnostic and therapeutic strategies.
Identifiants
pubmed: 30712769
pii: S0891-5520(18)30092-8
doi: 10.1016/j.idc.2018.10.005
pii:
doi:
Substances chimiques
Antiprotozoal Agents
0
liposomal amphotericin B
0
Amphotericin B
7XU7A7DROE
Types de publication
Journal Article
Research Support, Non-U.S. Gov't
Review
Langues
eng
Sous-ensembles de citation
IM
Pagination
79-99Informations de copyright
Copyright © 2018 The Author(s). Published by Elsevier Inc. All rights reserved.